Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Essential Thrombocythemia Channel

Explore the latest updates and expert interviews

Welcome to The Essential Thrombocythemia (ET) Channel

VJHemOnc provides the latest news in ET via on-demand podcasts, roundtable discussions, and exclusive video interviews with world-renowned experts.

Explore The ET Channel to learn more about key advances in the diagnosis, treatment, and management of ET presented at major international congresses.

Insights into the current role of ropeginterferon in the ET treatment landscape 3:31
Insights into the current role of ropeginterferon in the ET treatment landscape
Lucia Masarova • 4 Oct 2026
MPN Progression Registry: insights into the work of the MPN Research Foundation 19:15
MPN Progression Registry: insights into the work of the MPN Research Foundation
David Shoultz et al. • 2 Oct 2026
Emerging therapeutic strategies and future directions in MPNs 3:00
Emerging therapeutic strategies and future directions in MPNs
Lucia Masarova • 4 Oct 2026
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need? 2:21
Evolving treatment landscape in ET, PV, and MF: does MF still represent the greatest unmet need?
Prithviraj Bose • 18 Sep 2026
Emerging therapies and molecular approaches in essential thrombocythemia 1:44
Emerging therapies and molecular approaches in essential thrombocythemia
Aaron Gerds • 21 Sep 2026
Evolving treatment recommendations in myelofibrosis 1:35
Evolving treatment recommendations in myelofibrosis
Aaron Gerds • 21 Sep 2026
Optimizing MPN treatment strategies in community practice 1:23
Optimizing MPN treatment strategies in community practice
Aaron Gerds • 21 Sep 2026
Insights into the evolving treatment landscape for MPNs: current state and future directions 2:22
Insights into the evolving treatment landscape for MPNs: current state and future directions
Ruben Mesa • 12 Jun 2026
Targeting mutant CALR in MF and ET: the therapeutic potential of INCA33989 2:55
Targeting mutant CALR in MF and ET: the therapeutic potential of INCA33989
John Mascarenhas • 13 Jun 2026
SHORESPAN-017 extension data support the long-term safety of bomedemstat in MF and ET 1:11
SHORESPAN-017 extension data support the long-term safety of bomedemstat in MF and ET
Francesca Palandri • 12 Jun 2026
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs 3:58
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison • 13 Jun 2026
Ropeginterferon may redefine frontline and second-line treatment in ET 2:26
Ropeginterferon may redefine frontline and second-line treatment in ET
Lucia Masarova • 13 Jun 2026
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape 2:30
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
Lucia Masarova • 13 Jun 2026
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET 1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 13 Jun 2026
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial 2:28
Early versus delayed initiation of ropeginterferon alfa-2b in high-risk ET in the SURPASS-ET trial
Ruben Mesa • 12 Jun 2026
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs? 2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals